Sirnaomics Plans $300 Million Hong Kong IPO for RNAi Portfolio

Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, filed to raise $300 million in a Hong Kong IPO. Sirnaomics has two siRNA therapeutics that target TGF-β1 and COX-2 for either local or systemic administration to treat cancers and fibrotic diseases. Both are in Phase II trials in the US and China. The initial filing did not announce a financial goal for the offering, but data in the prospectus implied a $300 million target. Sirnaomics completed a $105 million Series E round earlier this month after raising the same amount in a Series D last year.

For further information, see ChinaBio Today (http://www.chinabiotoday.com/articles/siraonomics-300-million-hk-ipo)

Leave a Reply

Your email address will not be published. Required fields are marked *